Opportunity Information: Apply for RFA HL 16 021
Apply for RFA HL 16 021
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "NHLBI Progenitor Cell Translational Consortium (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837, 93.838, 93.839,.
- This funding opportunity was created on Nov 10, 2015 and posted on Nov 10, 2015.
- Applicants must submit their applications by Feb 08, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 5 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NHLBI Progenitor Cell Translational Consortium (PCTC) (U01) funding opportunity, issued by the National Heart, Lung, and Blood Institute (NHLBI) under NIH (HHS-NIH11), is a discretionary, cooperative agreement program designed to move progenitor cell science closer to real-world clinical and translational impact for heart, lung, and blood diseases. The central aim is to take advances in progenitor cell biology and push them beyond basic discovery into practical tools and interventions that can help explain disease, identify new therapeutic strategies, and ultimately support the development and application of cell-based treatments.
This initiative is structured around a consortium model, meaning awardees are expected to operate as part of a coordinated group rather than as fully independent projects. As a U01 cooperative agreement, the program anticipates substantial involvement from NHLBI in shaping and overseeing consortium activities, which typically includes shared goals, collaborative planning, alignment on standards and milestones, and active programmatic coordination. The focus is translational: projects should be positioned to bridge the gap between laboratory insights and tangible applications, rather than remaining purely descriptive or exploratory.
Programmatically, the PCTC emphasizes three interconnected research directions. First, it prioritizes progenitor cell-based disease models that can be used to understand disease mechanisms, including how diseases of the heart, lung, and blood start, progress, and respond to interventions. These models can include systems that recapitulate patient-relevant biology and allow researchers to test hypotheses in ways that are not feasible in humans. Second, it targets the development of novel therapies emerging from progenitor cell biology, which can include therapeutic concepts informed by cell behavior, differentiation capacity, regenerative mechanisms, or interactions with tissue environments. Third, it supports work aimed at the application of cell-based therapies for treatment, reflecting an interest in approaches where cells themselves (or cell-derived products, depending on the consortium scope) play a direct therapeutic role, with an eye toward eventual clinical relevance.
Eligibility is broad and includes a wide range of organizations that can contribute to translational research. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding higher education institutions where specified); for-profit organizations other than small businesses; and small businesses. The announcement also notes an "Others" category with additional eligibility details referenced in the full text, signaling that NHLBI allowed flexibility for other entity types when justified.
Administratively, the opportunity is identified as RFA HL 16 021. It falls under the health activity category and references CFDA numbers 93.837, 93.838, and 93.839, which align with NIH/NHLBI funding lines supporting cardiovascular, pulmonary, and hematologic research areas. The Funding Opportunity Announcement was created and posted on November 10, 2015, with an application closing date of February 8, 2016 (both original and current closing dates match, indicating no deadline extension in the provided data). NHLBI anticipated making about five awards. No award ceiling is listed in the provided information, suggesting applicants would need to consult the full FOA for budget limits, project period expectations, and any consortium-wide cost considerations.
Overall, this FOA is best understood as a coordinated translational push: it seeks teams that can use progenitor cell-based platforms to clarify disease biology, translate that knowledge into therapy concepts, and contribute to the development or testing of cell-based therapeutic strategies for heart, lung, and blood conditions, all within a consortium framework that emphasizes collaboration, shared progress, and active NIH involvement.
Frequently Asked Questions (FAQs): NHLBI Progenitor Cell Translational Consortium (PCTC) (U01)
What is this funding opportunity?
This is a National Heart, Lung, and Blood Institute (NHLBI) funding opportunity for the Progenitor Cell Translational Consortium (PCTC) using the U01 cooperative agreement mechanism. It is a discretionary program under NIH (HHS-NIH11) focused on advancing progenitor cell science toward real-world translational and clinical impact in heart, lung, and blood diseases.
What is the main goal of the PCTC (U01) program?
The central aim is to move advances in progenitor cell biology beyond basic discovery into practical tools and interventions. The program is intended to help explain disease, identify new therapeutic strategies, and support the development and application of cell-based treatments relevant to heart, lung, and blood conditions.
What does "translational" mean in the context of this FOA?
In this opportunity, "translational" emphasizes work that bridges laboratory insights and tangible applications. Projects are expected to go beyond purely descriptive or exploratory research and be positioned to contribute to practical models, therapeutic concepts, or treatment applications with eventual clinical relevance.
What is the funding mechanism and what does U01 imply?
The mechanism is a U01 cooperative agreement. This implies substantial involvement from NHLBI in shaping and overseeing consortium activities, including coordination around shared goals, collaborative planning, alignment on standards and milestones, and ongoing programmatic involvement.
Is this opportunity organized as a consortium?
Yes. The PCTC is explicitly structured around a consortium model. Awardees are expected to operate as part of a coordinated group rather than as fully independent projects.
How involved is NHLBI expected to be after awards are made?
Because it is a U01 cooperative agreement, NHLBI anticipates substantial involvement. This typically includes active programmatic coordination, shared planning, and oversight related to consortium goals, standards, and milestones.
What scientific areas or project types does the PCTC emphasize?
The program emphasizes three interconnected directions: (1) progenitor cell-based disease models to understand mechanisms of heart, lung, and blood diseases; (2) development of novel therapies emerging from progenitor cell biology; and (3) application of cell-based therapies for treatment with an eye toward eventual clinical relevance.
What kinds of disease models are encouraged?
Projects prioritizing progenitor cell-based disease models are encouraged when they help explain disease mechanisms, including how diseases start, progress, and respond to interventions. The description highlights models that recapitulate patient-relevant biology and allow hypothesis testing in ways not feasible in humans.
What does the FOA mean by "novel therapies emerging from progenitor cell biology"?
This refers to therapeutic concepts informed by progenitor cell behavior, differentiation capacity, regenerative mechanisms, and interactions with tissue environments. The emphasis is on translational development rather than basic characterization alone.
Does the FOA support direct cell-based treatments?
Yes. One of the three program directions is the application of cell-based therapies for treatment. The FOA describes interest in approaches where cells themselves (or cell-derived products, depending on the consortium scope) play a direct therapeutic role, with attention to eventual clinical relevance.
Which disease areas are in scope?
The scope covers diseases of the heart, lung, and blood, consistent with NHLBI’s mission areas and the program’s focus on cardiovascular, pulmonary, and hematologic conditions.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding higher education institutions where specified); for-profit organizations other than small businesses; and small businesses.
Is there any additional or flexible eligibility beyond the listed categories?
Yes. The announcement notes an "Others" category with additional eligibility details referenced in the full text, indicating flexibility for other entity types when justified.
What is the FOA identifier for this opportunity?
The opportunity is identified as RFA HL 16 021.
Which agency and institute are sponsoring this program?
The sponsor is the National Heart, Lung, and Blood Institute (NHLBI) under the National Institutes of Health (NIH).
What is the activity category for this opportunity?
The activity category is listed as Health.
Which CFDA numbers are associated with this FOA?
The FOA references CFDA numbers 93.837, 93.838, and 93.839, aligning with NIH/NHLBI funding lines supporting cardiovascular, pulmonary, and hematologic research areas.
When was the funding opportunity announcement created and posted?
The FOA was created and posted on November 10, 2015.
What was the application due date?
The application closing date is February 8, 2016. The original and current closing dates match in the provided information, indicating no deadline extension in that data.
How many awards did NHLBI anticipate making?
NHLBI anticipated making about five awards.
Is there an award ceiling or budget cap listed in the provided information?
No award ceiling is listed in the provided information. Applicants would need to consult the full FOA for budget limits, project period expectations, and any consortium-wide cost considerations.
What should applicants keep in mind about collaboration expectations?
This program is designed for coordinated, consortium-based work. The description indicates expectations for collaborative planning, shared goals, alignment on standards and milestones, and participation in active programmatic coordination with NHLBI involvement.
What is the overall purpose of the consortium approach in this FOA?
The consortium approach is intended to create a coordinated translational push where teams collectively use progenitor cell-based platforms to clarify disease biology, translate findings into therapeutic strategies, and contribute to the development or testing of cell-based therapeutic approaches for heart, lung, and blood diseases.
Browse more opportunities from the same category: Health
Next opportunity: MBDA Business Consulting Project
Previous opportunity: Adaptation/Optimization of Technology (ADOPTech) to Support Social Functioning (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 16 021
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 16 021) also looked into and applied for these:
| Funding Opportunity |
|---|
| Medical Monitoring Project (MMP) Apply for CDC RFA PS15 150302CONT16 Funding Number: CDC RFA PS15 150302CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Demographic Surveillance Study Support in the Republic of Mozambique under President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 11101SUPP Funding Number: CDC RFA GH11 11101SUPP Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Provision of comprehensive HIV/AIDS and TB services including prevention, care, support and treatment to prisoners and staff of the prisons service in the Republic of Uganda under the President’s Emergency Plan for AIDS Relief Apply for CDC RFA GH15 159002CONT16 Funding Number: CDC RFA GH15 159002CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01) Apply for PAR 16 021 Funding Number: PAR 16 021 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Limited Competition: Pediatric Heart Network for the Data Coordinating Center (U24) Apply for RFA HL 17 005 Funding Number: RFA HL 17 005 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Emergency Medical Services for Children Innovation and Improvement Center Apply for HRSA 16 052 Funding Number: HRSA 16 052 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Statewide Family Network Program Apply for SM 16 004 Funding Number: SM 16 004 Agency: HHS-SAMHS Category: Health Funding Amount: $95,000 |
| State Offices of Rural Health Grant Program (SORH) Apply for HRSA 16 016 Funding Number: HRSA 16 016 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Precision Medicine Initiative Cohort Program Healthcare Provider Organization Enrollment Centers (UG3/UH3) Apply for RFA PM 16 002 Funding Number: RFA PM 16 002 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| National State-Based Tobacco Control Programs Apply for CDC RFA DP15 150902CONT16 Funding Number: CDC RFA DP15 150902CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| NIH Director's Early Independence Awards (DP5) Apply for RFA RM 15 006 Funding Number: RFA RM 15 006 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| Pre-clinical Research Based on Existing Repurposing Tools Apply for RFA TR 16 001 Funding Number: RFA TR 16 001 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| Precision Medicine Initiative Cohort Program Participant Technologies Center (U24) Apply for RFA PM 16 003 Funding Number: RFA PM 16 003 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Noncommunicable Disease Prevention and Health Promotion in the Region of the Americas, PAHO Apply for CDC RFA GH15 161802CONT16 Funding Number: CDC RFA GH15 161802CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Pediatric Heart Network Clinical Research Centers (UG1) Apply for RFA HL 17 004 Funding Number: RFA HL 17 004 Agency: HHS-NIH11 Category: Health Funding Amount: $220,000 |
| MCH Pipeline Training Program Apply for HRSA 16 037 Funding Number: HRSA 16 037 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Ensuring Adequate Access to HIV/AIDS Screening, Care and Treatment to Key Populations in Haiti under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1682 Funding Number: CDC RFA GH16 1682 Agency: HHS-CDC-CGH Category: Health Funding Amount: $1,200,000 |
| Supporting the National Blood Transfusion Service (NBTS) in the implementation and expansion of Blood Safety activities in the Republic of Zambia under the President’s Emergency plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1709 Funding Number: CDC RFA GH16 1709 Agency: HHS-CDC Category: Health Funding Amount: $1,353,644 |
| Strengthening HIV/AIDS Prevention and Care Services for Highly Vulnerable Populations in the Republic of Côte d’Ivoire Under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10310501SUPP16 Funding Number: CDC RFA PS10 10310501SUPP16 Agency: HHS-CDC Category: Health Funding Amount: $3,123,298 |
| National Child Traumatic Stress Initiative, National Center for Child Traumatic Stress Apply for SM 16 003 Funding Number: SM 16 003 Agency: HHS-SAMHS Category: Health Funding Amount: $6,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 16 021", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.